skip to Main Content
August 8, 2017

Codexis Obtains Court Order Awarding Summary Judgment of Patent Infringement against EnzymeWorks

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Aug. 8, 2017–
Codexis,
Inc.
(NASDAQ: CDXS), a leading protein engineering company, on
Tuesday secured a federal court order awarding it summary judgment on 10
claims of patent infringement it brought in a lawsuit against Suzhou,
China-based EnzymeWorks, Inc. and its San Diego-based affiliate, also
called EnzymeWorks, Inc. The court’s order establishes EnzymeWorks’
uncontested infringement of 10 of Codexis’ patents and eliminates any
need for a trial on those issues. The 10 Codexis patents cover dozens of
engineered enzymes that have wide industrial applicability.

In the lawsuit, filed in February 2016 in United States District Court
for the Northern District of California
in San Francisco, Codexis sued
EnzymeWorks and EnzymeWorks founder Junhua “Alex” Tao for willful
infringement of 10 biocatalysis patents and also for trade secret
misappropriation, breach of contract, interference with business
relationships and unfair competition. After nearly 18 months of legal
process, EnzymeWorks never contested the infringement charges or
challenged the validity of Codexis’ patents. This set the stage for
District Judge William H. Orrick awarding Codexis summary judgment of
patent infringement.

The court’s order was based on a stipulation in which EnzymeWorks
acknowledged that it “has not denied or disputed its infringement” of
Codexis’ 10 patents, or the validity of those patents. This partial
summary judgment order in favor of Codexis is a key milestone in the
lawsuit, but additional disputes remain to be resolved at a jury trial.

Those continuing disputes include Tao’s individual liability for the
infringement, Codexis’ claims that the infringement was willful and the
amount of damages to be awarded to Codexis, and they also include
several claims arising under California state law.

“Codexis is pleased to finally have some closure about EnzymeWorks’
blatant infringement of our patents and disrespect for U.S. patent
laws,” said John
Nicols
, CEO and president of Codexis. “Like our customers and
shareholders, Codexis relies on intellectual property rights, and we are
grateful that the legal process vindicated our claims and protects our
innovations.”

Nicols added, “We’re confident that once the court and a San Francisco
Bay Area
jury hear all of the facts, they will award significant damages
to Codexis reflecting the tremendous value EnzymeWorks and Tao illegally
obtained by deliberately infringing our patents, stealing our trade
secrets and breaching our contracts.” Nicols noted that Codexis spent
several hundred million dollars in innovating and developing proprietary
biocatalysis technologies over the company’s 15-plus year history.

About Codexis, Inc.
Codexis, Inc. is a leading protein
engineering company that applies its technology to the development of
biocatalysts for commercial manufacture of pharmaceuticals and fine
chemicals, as well as the development of enzymes as biotherapeutics and
for molecular diagnostics. Codexis’ proven technology enables
implementation of biocatalytic solutions to meet customer needs for
rapid, cost-effective and sustainable manufacturing. For more
information, see www.codexis.com.

Forward-Looking Statements
This press release contains
forward-looking statements relating to the lawsuit that Codexis filed
against EnzymeWorks and Junhua “Alex” Tao for patent infringement,
misappropriation of trade secrets, and other claims, including the
potential outcome of such litigation. You should not place undue
reliance on these forward-looking statements because they involve known
and unknown risks, uncertainties and other factors that are, in some
cases, beyond Codexis’ control and that could materially affect actual
results. Factors that could materially affect actual results include
that Codexis may not prevail on some or all of its legal claims against
Tao and EnzymeWorks; Codexis may be involved in additional lawsuits to
protect or enforce its patents or other rights, which could be
expensive, time-consuming and unsuccessful; Codexis’ ability to compete
may decline if it does not adequately protect its proprietary
technologies or if it loses some of its intellectual property rights;
Codexis may not be able to enforce its intellectual property rights
throughout the world; if Codexis’ biocatalysts, or the genes that code
for its biocatalysts, are stolen or misappropriated, others could use
these biocatalysts or genes to produce competing products; third parties
may claim that Codexis is infringing their intellectual property rights
or other proprietary rights, which may subject Codexis to costly and
time-consuming litigation and prevent Codexis from developing or
commercializing its products; and confidentiality agreements with
employees and others may not adequately prevent disclosures of trade
secrets and other proprietary information. Additional factors that could
materially affect actual results can be found in Codexis’ Annual Report
on Form 10-K filed with the Securities and Exchange Commission (“SEC”)
on March 9, 2017, including under the caption “Risk Factors,” and in
Codexis’ Quarterly Report on Form 10-Q filed with the SEC on May 9,
2017
. Codexis expressly disclaims any intent or obligation to update
these forward-looking statements, except as required by law.

Source: Codexis

For Codexis
LHA Investor Relations
Jody Cain,
310-691-7100
jcain@lhai.com
or
SCORR
Marketing

Lea Studer, 308-237-5567
Senior Vice President
of Marketing Communications
lea@scorrmarketing.com

Back To Top
Close search
Search